CAMP4 Therapeutics Corporation

NasdaqGM CAMP

CAMP4 Therapeutics Corporation Free Cash Flow for the Trailing 12 Months (TTM) ending November 30, 2023: USD -3.08 M

CAMP4 Therapeutics Corporation Free Cash Flow is USD -3.08 M for the Trailing 12 Months (TTM) ending November 30, 2023, a 92.60% change year over year. Free cash flow is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

CAMP4 Therapeutics Corporation Free Cash Flow for the Trailing 12 Months (TTM) ending November 30, 2022 was USD -41.62 M, a -1,263.31% change year over year.
CAMP4 Therapeutics Corporation Free Cash Flow for the Trailing 12 Months (TTM) ending November 30, 2021 was USD -3.05 M, a -118.02% change year over year.
CAMP4 Therapeutics Corporation Free Cash Flow for the Trailing 12 Months (TTM) ending November 30, 2020 was USD 16.94 M, a 195.11% change year over year.
CAMP4 Therapeutics Corporation Free Cash Flow for the Trailing 12 Months (TTM) ending November 30, 2019 was USD -17.81 M, a -139.58% change year over year.

Key data

Date	Free Cash Flow	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities

NasdaqGM: CAMP

CAMP4 Therapeutics Corporation

CEO	Mr. Joshua Mandel-Brehm
IPO Date	Oct. 11, 2024
Location	United States
Headquarters	One Kendall Square Bldg 1400 West, 3rd Floor
Employees	58
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

CAMP4 Therapeutics Corp. operates as a biotechnology company which engages in the discovery of treatment options for patients. The company was founded by Richard A. Young and Leonard Zon in 2015 and is headquartered in Cambridge, MA.

Key trends

Past 5 years